Harvey Snyder, MD
Cardiovascular Disease · Haddon Heights, NJNPI 1003869488
Payments from drug & device makers
Across 505 payments — averaging $183.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$29K
- AstraZeneca$27K
- Astrazeneca UK Limited$18K
- Merck$12K
- Novartis$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$915
- plus $4K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 55 | $29,352 |
| AstraZeneca | 17 | $27,077 |
| Astrazeneca UK Limited | 4 | $18,369 |
| Merck | 23 | $12,157 |
| Novartis | 118 | $1,331 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 70 | $915 |
| Impulse Dynamics (USA) Inc. | 26 | $649 |
| E.r. Squibb & Sons, L.L.C. | 35 | $345 |
| Johnson & Johnson | 23 | $340 |
| Amgen | 23 | $329 |
| Pfizer | 22 | $327 |
| Abbott | 9 | $283 |
| Amarin Pharma, Inc. | 21 | $274 |
| Kowa Pharmaceuticals America, Inc. | 10 | $141 |
| Bayer | 6 | $108 |
| Atricure, Inc. | 3 | $87 |
| Regeneron Healthcare Solutions, Inc. | 5 | $81 |
| Novo Nordisk | 5 | $72 |
| Boehringer Ingelheim | 5 | $68 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $60 |
| Sanofi-aventis U.S. LLC | 4 | $54 |
| Boston Scientific | 2 | $53 |
| Edwards Lifesciences | 2 | $39 |
| W. L. Gore & Associates, Inc. | 2 | $31 |
| Kestra Medical Technology Services, Inc. | 2 | $30 |
| Tactile Systems Technology Inc | 1 | $24 |
| Sanofi | 1 | $20 |
| GSK | 1 | $18 |
| Regeneron | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Heartflow, Inc. | 1 | $14 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $13 |
How this compares
$92,724 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Haddon Heights
- Mark GelerntHaddon Heights$2M
- Dilip ViswanathHaddon Heights$1.8M
- Sanford GipsHaddon Heights$668K
- Andreas PavlidesHaddon Heights$598K
- Vijayendra VermaHaddon Heights$359K
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Robert FishbergSpringfield$1.9M
- Marc CohenNewark$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.